Crossmark

Trimetazidine and allopurinol for the prevention of Contrast-associated acute kidney injury in elective percutaneous coronary intervention: a randomized controlled trial

Crossref DOI link: https://doi.org/10.1007/s00228-025-03985-6

Published Online: 2026-01-22

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ali, Nourhan Osama

Bazan, Naglaa Samir https://orcid.org/0000-0002-8930-4697
Mowafy, Hatem Hossam

Abdelrahim, Mohamed E.A.

Harb, Hadeer S. https://orcid.org/0000-0003-2259-9686
Funding

Funding for this research was provided by:

Beni Suef University
License Information

Text and Data Mining valid from 2026-01-22

Version of Record valid from 2026-01-22
More Information

Article History

Received: 2 June 2025

Accepted: 12 December 2025

First Online: 22 January 2026

Declarations

:

: This study was approved by the Research Ethics Committee of the Faculty of Medicine, Cairo University (Approval No. S-2-2022, dated July 17, 2022) and was registered on ClinicalTrials.gov (Clinical Trial Identifier: NCT05540184; Release Date: September 5, 2022, ). Written informed consent was obtained from all participants prior to their inclusion in the study, in accordance with the Declaration of Helsinki.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below